Creatinine variation improves Zwolle score in selecting low-risk patients after ST-segment elevation myocardial infarction. Issue 6 (September 2021)

• Record Type: Journal Article
• Authors: Rodrigues Brás, Diogo; Gomes, António; Semedo, Pedro; Santos, Ana Rita; Cordeiro Piçarra, Bruno; Carrington, Mafalda; Pais, João; Rocha, Ana Rita; Congo, Kisa; Neves, David; Bento, Ângela; Fernandes, Renato; Trinca, Manuel; Patrício, Lino
• Is Part Of: Coronary artery disease. Volume 32:Issue 6(2021)
• Publication Date: 2021-09
• Subjects: coronary artery disease -- creatinine -- early discharge -- low-risk -- renal function -- ST-segment elevation myocardial infarction -- Zwolle score; Coronary heart disease -- Periodicals; Coronary Disease -- Indexes; Coronary Disease -- Periodicals; 616.123005
• DOI: 10.1097/MCA.0000000000001002
• Languages: English
• ISSNs: 0954-6928

Abstract

Abstract : Background: The Zwolle score is recommended to identify ST-segment elevation myocardial infarction (STEMI) patients with low-risk eligible for early discharge. Our aim was to ascertain if creatinine variation (Δ-sCr) would improve Zwolle score in the decision-making of early discharge after primary percutaneous coronary intervention (PCI). Methods and results: A total of 3296 patients with STEMI that underwent primary PCI were gathered from the Portuguese Registry on Acute Coronary Syndromes. A Modified-Zwolle score, including Δ-sCr, was created and compared with the original Zwolle score. Δ-sCr was also compared between low (Zwolle score ⩽3) and non-low-risk patients (Zwolle score >3). The primary endpoint is 30-day mortality and the secondary endpoints are in-hospital mortality and complications. Thirty-day mortality was 1.5% in low-risk patients (35 patients) and 9.2% in non-low-risk patients (92 patients). The Modified-Zwolle score had a better performance than the original Zwolle score in all endpoints: 30-day mortality (area under curve 0.853 versus 0.810, P < 0.001), in-hospital mortality (0.889 versus 0.845, P < 0.001) and complications (0.728 versus 0.719, P = 0.037). Reclassification of patients lead to a net reclassification improvement of 6.8%. Additionally, both original Zwolle score low-risk patients and non-low-risk patients who had a Δ-sCr ≥0.3 mg/dl had higher 30-day mortality (low-risk: 1% versus 6.6%, P < 0.001; non-low-risk 4.4% versus 20.7%, P < 0.001), in-hospital mortality and complications. Conclusion: Δ-sCr enhanced the performance of Zwolle score and was associated with higher 30-day mortality, in-hospital mortality and complications in low and non-low-risk patients. This data may assist the selection of low-risk patients who will safely benefit from early discharge after STEMI. Abstract : Supplemental Digital Content is available in the text.